[Dorsey & Whitney Letterhead]
March 18, 2002
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Attn: Filing Desk
Re: Enzon, Inc.- Current Report on Form 8-K
Ladies and Gentlemen:
On behalf of our client Enzon, Inc. (the "Company"), we are transmitting
electronically the Company's Current Report on Form 8-K (the "Form 8-K") dated
March 18, 2002.
Please note that the Form 8-K filed herewith contains a conformed
signature and that an original, manual signature will be retained in the
Company's records for five (5) years.
Very truly yours,
By: /s/ KENNETH K. KWOK
-------------------
Kenneth K. Kwok
cc: Kenneth J. Zuerblis
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) March 18, 2002
ENZON, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-12957 22-2372868
(State or other jurisdiction of (Commission (IRS Employer
incorporation) File Number) Identification)
20 Kingsbridge Road, Piscataway, New Jersey 08854
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (732) 980-4500
NA
(Former name or former address, if changed since last report)
Item 5. Other Events
On March 18, 2002, Enzon, Inc. (the "Company") announced the appointment
of Ulrich M. Grau, Ph.D. as the Company's Chief Scientific Officer. In this
role, Dr. Grau will be responsible for advancing the Company's product pipeline,
expanding its research and development programs and technological base, and
advising the board and management on the scientific vision and direction of the
Company.
Dr. Grau brings over 20 years of experience from the biotechnology and
pharmaceutical industry having directed numerous R&D programs. Most notably, Dr.
Grau served as President of Research and Development at BASF Pharma and Senior
VP Global Product Realization for Hoechst Marion Roussel. While at BASF, Dr.
Grau directed a global R&D organization of approximately 1,500 employees, and
significantly advanced and expanded the Company's product portfolio. At Hoechst,
Dr. Grau served as Senior VP Global Product Realization, where he directed the
company's late-stage product development activities.
Jeffrey McGuire, Ph.D. has been named the Company's Senior Vice President
of Scientific Affairs. In this capacity, Dr. McGuire will be reporting to Dr.
Grau and will be focused on identifying and gaining access to new preclinical
candidates and drug delivery technologies to expand the Company's proprietary
pipeline.
EXCEPT FOR THE HISTORICAL INFORMATION HEREIN, THE MATTERS DISCUSSED IN
THIS NEWS RELEASE INCLUDE FORWARD-LOOKING STATEMENTS THAT MAY INVOLVE A NUMBER
OF RISKS AND UNCERTAINTIES. ACTUAL RESULTS MAY VARY SIGNIFICANTLY BASED UPON A
NUMBER OF FACTORS, WHICH ARE DESCRIBED IN THE COMPANY'S FORM 10-K, FORM 10-Q'S
AND FORM 8-K'S ON FILE WITH THE SEC, INCLUDING WITHOUT LIMITATION, RISKS IN
OBTAINING AND MAINTAINING REGULATORY APPROVAL FOR INDICATIONS AND EXPANDED
INDICATIONS, MARKET ACCEPTANCE OF AND CONTINUING DEMAND FOR THE COMPANY'S
PRODUCTS AND THE IMPACT OF COMPETITIVE PRODUCTS AND PRICING.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: March 18, 2002
ENZON, INC.
-----------
(Registrant)
By:/s/ KENNETH J. ZUERBLIS
--------------------------
Kenneth J. Zuerblis
Vice President, Finance, Chief Financial
Officer and Corporate Secretary